Summary:
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Efficacy and Safety of Once Daily Centanafadine Capsules for the Treatment of Adolescents With Attention-deficit/Hyperactivity Disorde
11 study visits will be required over a 12 week period
Qualified Participants Must:
• Adolescents must be between the ages of 13-17
• Suffering from ADHD symptoms (your child does not need to be diagnosed to be considered for this study)
• Must be willing to attend the study office visits and complete all study assessments.
• After the completion of this study, your child may qualify to participate in an open label long term study where they will receive the actual study medication and not a placebo
Qualified Participants May Receive:
-Reimbursement for time and travel of $75 will be provided per study visit
-Free study related medication and study related doctor visits
-Transportation may be provided